This multicenter, prospective, observational study aims to generate and analyze real-world data on the effectiveness and safety of Ruscus aculeatus L. treatment in patients with symptomatic chronic venous disease classified as CEAP C1-C6. Patients receiving Ruscus aculeatus L. as part of routine clinical practice will be followed for 90 days without any study-mandated intervention. Disease severity will be assessed using the revised Venous Clinical Severity Score (rVCSS), pain using the Visual Analog Scale (VAS), quality of life using the Chronic Venous Disease Quality of Life Questionnaire (CIVIQ-20), treatment adherence using the Visual Analog Scale for adherence (VAS-U), and safety through the collection of adverse events during the observation period.
Adults aged 18 to 75 years.
Patients prescribed Ruscus aculeatus L. as part of routine clinical practice, with the baseline visit performed within 7 days after treatment initiation.
Symptomatic chronic venous disease classified as CEAP (2020) C1-C6.
Willing and able to provide written informed consent and complete study as sessments.
Symptomatic patients classified as CEAP C0.
Uncontrolled hypertension.
Lower extremity dermatitis or ulcer related to peripheral arterial disease or diabetes.
Neurological or orthopedic conditions limiting mobility or independent walking.